Pharmacotherapies for COPD

46Citations
Citations of this article
164Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines. © the author(s), publisher and licensee Libertas Academica Ltd.

Cite

CITATION STYLE

APA

Ejiofor, S., & Turner, A. M. (2013). Pharmacotherapies for COPD. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. https://doi.org/10.4137/CCRPM.S7211

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free